BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $11.
BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $11.